Use of vegfr1 as a biomarker
AssigneeSilence Therapeutics GmbH
InventorsKLAUS GIESE, JOERG KAUFMANN
Life of this patent
Estimating the term…
Abstract
The present invention is related to the use of VEGFR1 or of a nucleic acid coding for VEGFR1 as a biomarker in a method for the treatment of a subject, wherein the method for the treatment comprises administering to the subject a PKN3 inhibitor.
Claims24
A method for deciding whether a subject is a responder to a method of treatment, wherein the method of treatment comprises administering to the subject a PKN3 inhibitor, comprising:
- determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject prior to the subject being subjected to the method of treatment,
- determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject after the subject having been subjected to the method of treatment;
- wherein if the level of a VEGFR1 or a nucleic acid coding for a VEGFR1 in a sample from the subject after the subject having been subjected to the method of treatment is decreased compared to the level of a VEGFR1 or a nucleic acid coding for a VEGFR1 in a sample from the subject prior to the subject having being subjected to the method of treatment, the subject is a responder to the method of treatment.
A method for deciding whether a subject having undergone a first method of treatment, wherein the first method of treatment comprises administering to the subject a PKN3 inhibitor, shall be subject to a second method of treatment, wherein the second method of treatment comprises administering to the subject a PKN3 inhibitor, comprising:
- determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject prior to a first method of treatment,
- determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject after a first period of time after the first method of treatment, and
- optionally determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject after a second period of time after the first method of treatment,
- wherein if the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject after the first or second period of time after the first method of treatment is increased compared to the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject prior to a first method of treatment, the subject is to be subjected to the second method of treatment.
A method for deciding whether a subject shall undergo a method of treatment, whereby the method of treatment comprises the administration of a PKN3 inhibitor, comprising determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1, or determining the expression level of a VEGFR1 or of a nucleic acid coding for a VEGFR1, wherein if the expression level of a VEGFR1 or of a nucleic acid coding for a VEGFR1, expressed as titre of VEGF1 in blood or plasma of the subject, is equal to or greater than 200 pg/ml, the patient is amenable to the method of treatment comprising administration of a PKN3 inhibitor.
A method for the treatment of a subject suffering from or being at risk of suffering from a disease associated with the expression level of a VEGFR1 or of a nucleic acid coding for a VEGFR1, said expression level being expressed as titre of a VEGF1 in blood or plasma of the subject that is equal to or greater than 200 pg/ml, comprising measuring the expression level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in said subject and administering a PKN3 inhibitor to said subject having an expression level that is equal to or greater than 200 pg/ml.
Dependencies are inferred from the claim text.